CohBar, Inc. (CWBR)
$2.73
Rating:
Recommendation:
Neutral
| Symbol | CWBR |
|---|---|
| Price | $2.73 |
| Beta | 1.792 |
| Volume Avg. | 0.03M |
| Market Cap | 7.936M |
| Shares () | - |
| 52 Week Range | 1.5-10.53 |
| 1y Target Est | - |
| DCF Unlevered | CWBR DCF -> | |
|---|---|---|
| DCF Levered | CWBR LDCF -> | |
| ROE | -108.34% | Strong Sell |
| ROA | -123.65% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 2.92% | Neutral |
| P/E | - | |
| P/B | 0.42 | Neutral |
Latest CWBR news
About
Download (Excel)CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.